TY - JOUR T1 - NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 937 LP - 943 DO - 10.2967/jnumed.118.230607 VL - 60 IS - 7 AU - Thomas A. Hope AU - Amanda Abbott AU - Karen Colucci AU - David L. Bushnell AU - Linda Gardner AU - William S. Graham AU - Sheila Lindsay AU - David C. Metz AU - Daniel A. Pryma AU - Michael G. Stabin AU - Jonathan R. Strosberg Y1 - 2019/07/01 UR - http://jnm.snmjournals.org/content/60/7/937.abstract N2 - With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing. Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear Medicine and Molecular Imaging collaborated to develop a practical consensus guideline for the administration of 177Lu-DOTATATE. In this paper, we discuss patient screening, maintenance somatostatin analog therapy requirements, treatment location and room preparation, drug administration, and patient release as well as strategies for radiation safety, toxicity monitoring, management of potential complications, and follow-up. Controversies regarding the role of radiation dosimetry are discussed as well. This document is designed to provide practical guidance on how to safely treat patients with this therapy. ER -